Cancer Discovery

Cancer Discovery is a monthly peer-reviewed journal published by the American Association for Cancer Research and launched in 2011, covering basic, translational and clinical cancer research, with a 2025 Journal Impact Factor of 29.5《癌症发现》由美国癌症研究协会（American Association for Cancer Research，AACR）出版、2011 年创办的月刊同行评审期刊，涵盖基础、转化与临床肿瘤研究，2025 年影响因子为 29.5。

Scope

• It publishes high-impact, peer-reviewed articles describing major advances in basic, translational and clinical cancer research and clinical trials该刊刊载高影响力、经同行评审的文章，报道基础、转化与临床肿瘤研究及临床试验的重大进展。^[1]
• As the premier cancer information resource, it also presents review articles, perspectives and commentaries, news stories and Research Watch summaries of important articles作为权威的癌症信息资源，该刊还刊载综述文章、观点与评论、新闻故事，以及对重要论文的（Research Watch）摘要。
• Topics span the spectrum of cancer science and medicine, from the laboratory to the clinic and to epidemiologic and population science其主题横跨肿瘤科学与医学的各个层面，从实验室到临床，直至流行病学与人群科学。
• Articles are posted online daily and collected into monthly issues, with 12 issues and one volume per year论文每日在线先行发布，并按月汇集成刊，每年 12 期、每年一卷。
• Manuscripts are stringently reviewed for high standards of scientific merit, and only those reporting novel, timely and broadly significant research are accepted稿件经过严格评审以确保高标准的科学价值，只有报道新颖、及时且意义广泛的研究才被接收。
• It is part of the AACR's portfolio of 10 peer-reviewed journals, and authors may publish open access under a Creative Commons license该刊是（AACR）旗下 10 种同行评审期刊之一，作者可依知识共享许可选择开放获取出版。

History

• The AACR launched Cancer Discovery in 2011 as its seventh journal, addressing the community's need for a journal that published the most impactful research with streamlined editorial processes（AACR）于 2011 年创办该刊，为其第七种期刊，回应学界对一种既刊载最高影响力研究又具备高效编辑流程的期刊的需求。
• Its founding editors-in-chief were Lewis C. Cantley, PhD, and the late Jose Baselga, MD, PhD其创始主编为 Lewis C. Cantley（博士）与已故的 Jose Baselga（医学博士）。
• Cantley served as founding editor-in-chief from 2011 to 2026, most recently alongside Luis A. Diaz JrCantley 自 2011 年至 2026 年担任创始主编，后期与 Luis A. Diaz Jr 共同执掌。
• Luis A. Diaz Jr has served as editor-in-chief since 2019Luis A. Diaz Jr 自 2019 年起担任主编。
• Matthew Vander Heiden, MD, PhD, was appointed editor-in-chief in 2026 and serves alongside DiazMatthew Vander Heiden（医学博士、博士）于 2026 年被任命为主编，与 Diaz 共同任职。
• It marked its 10th anniversary in 2021 and publishes monthly from the AACR office in Philadelphia, with a 2025 Journal Impact Factor of 29.5该刊于 2021 年迎来十周年，由（AACR）位于费城的编辑部按月出版，2025 年影响因子为 29.5。

Editors

• The editors-in-chief are Matthew G. Vander Heiden and Luis A. Diaz现任主编为 Matthew G. Vander Heiden 与 Luis A. Diaz。
• Vander Heiden is director of the Koch Institute for Integrative Cancer Research at MIT, a professor of biology at MIT and an oncologist at Dana-Farber Cancer InstituteVander Heiden 是（MIT）科赫综合癌症研究所所长、（MIT）生物学教授，并在（Dana-Farber Cancer Institute）任肿瘤科医师。
• He is internationally recognized for uncovering the roles of fundamental metabolic pathways in cancer onset and progression, including an alternative glycolytic pathway in cancer cells他在揭示基础代谢通路于癌症发生与进展中的作用方面享有国际声誉，其中包括癌细胞中的替代糖酵解通路。
• Diaz has served as editor-in-chief since 2019, and the two lead the journal with the Editorial Board and journal staffDiaz 自 2019 年起担任主编，二人与编委会及期刊工作人员共同执掌该刊。
• Scientific editors include James P. Allison and Carlos L. Arteaga, and review follows the AACR's shared editorial process and policies科学编辑包括 James P. Allison 与 Carlos L. Arteaga，评审遵循（AACR）统一的编辑流程与政策。^[2]